clinical trial · NCT07115745
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company·phase1·recruiting·n = 125
Refractory Autoimmune DiseasesBMS-986515FludarabineCyclophosphamideTocilizumab
brief summary
The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory autoimmune diseases.
started
Sep 4, 2025
primary completion
Mar 15, 2029
completion
Aug 16, 2030
last updated
Mar 4, 2026
official title
A Phase 1, Multicenter, Open-label Study of BMS-986515, Healthy Donor Allogeneic CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Autoimmune Diseases
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol